EN DE
STOCK COMPARISON

Feng Chi Biotech vs Vertex Pharmaceuticals: Fair Value & Quality

Both stocks run through our valuation models. Here is how Feng Chi Biotech (6744) and Vertex Pharmaceuticals (VRTX) compare, as of Aug 11, 2026.

As of Aug 11, 2026, Fair Value Calculator sees Feng Chi Biotech as the less overvalued of the two: Feng Chi Biotech trades at TWD 14.70 versus a fair value of TWD 12.01 (-18%), while Vertex Pharmaceuticals trades at $496 versus $279 (-44%).
Feng Chi Biotech
6744.TWO · TWD · Healthcare
-18%
upside to fair value
overvalued
PriceTWD 14.70
Fair ValueTWD 12.01
Quality55/100
Vertex Pharmaceuticals
VRTX · USD · Health Care
-44%
upside to fair value
overvalued
Price$496
Fair Value$279
Quality79/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Feng Chi BiotechVertex Pharmaceuticals
Valuation
16.2×P/E (TTM)28.8×
1.32×P/S (TTM)10.06×
0.98×P/B6.59×
9.3×EV/EBITDA23.8×
PEG1.72×
Profitability
8%Net margin36%
5%Operating margin38%
6%Return on equity24%
3%Return on assets12%
Growth
-3%Revenue growth (YoY)8%
-2.9%Avg. growth/yr (3Y)10.6%
-0.2%Avg. growth/yr (5Y)14.2%
Balance & size
Debt / equity0.03×
$7MMarket cap$123B
weakGrowth qualityhealthy

Vertex Pharmaceuticals leads: 4 to 7 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Feng Chi Biotechof which business quality 54 · market factors 33 Vertex Pharmaceuticalsof which business quality 77 · market factors 65
ProfitabilityMargins and returns on capital today
41
72
Quality GrowthAre margins and returns improving?
41
65
CashflowEarnings quality: real cash, not paper profit
5
79
Fin. StrengthBalance sheet, leverage, solvency risk
84
92
InvestmentDisciplined investing over empire-building
89
58
Low VolatilityCalm price path (market factor)
60
86
MomentumPrice trend over the last 3–12 months (market factor)
24
54
52W MomentumDistance to the 52-week high (market factor)
19
59
Net IssuanceBuybacks instead of dilution
84
82

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Feng Chi Biotech

DCF ModelsTWD 9.09
Earnings-BasedTWD 7.50
Dividend DiscountTWD 7.44
MultiplesTWD 16.65
Asset-BasedTWD 10.44
Economic ProfitTWD 8.88
Growth EarningsTWD 14.25

10 of 15 models see the stock below the current price.

Vertex Pharmaceuticals

DCF Models$453
Earnings-Based$516
Dividend Discount$7.07
Multiples$278
Asset-Based$49.27
Growth DCF$348
Economic Profit$254
Growth Earnings$692

18 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Feng Chi Biotech
Bear TWD 9.97Fair Value TWD 12.01Bull TWD 12.01
TWD 14.70 = current price (white tick)
Vertex Pharmaceuticals
Bear $210Fair Value $279Bull $900
$496 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Feng Chi Biotech · Healthcare

Quality score55 · above median
Fair value upside-18% · above median

Vertex Pharmaceuticals · Health Care

Quality score79 · Top 25%
Fair value upside-44% · below median

Bottom line

As of Aug 11, 2026, Fair Value Calculator sees Feng Chi Biotech as the less overvalued of the two: Feng Chi Biotech trades at TWD 14.70 versus a fair value of TWD 12.01 (-18%), while Vertex Pharmaceuticals trades at $496 versus $279 (-44%).

Vertex Pharmaceuticals has the higher quality score (79/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.